Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol in active axial spondyloarthritis
NL-OMON36612Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Sep 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), sponsored by UCB. Started Sep 2010; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON36612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36612.